Cargando…
SAGE-217, A Novel GABA(A) Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies
BACKGROUND: SAGE-217, a novel γ-aminobutyric acid A (GABA(A)) receptor positive allosteric modulator, was evaluated in phase I, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) studies to assess the safety and pharmacokinetics (PK) of SAGE-217 following...
Autores principales: | Hoffmann, Ethan, Nomikos, George G., Kaul, Inder, Raines, Shane, Wald, Jeff, Bullock, Amy, Sankoh, Abdul J., Doherty, James, Kanes, Stephen J., Colquhoun, Helen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994455/ https://www.ncbi.nlm.nih.gov/pubmed/31338688 http://dx.doi.org/10.1007/s40262-019-00801-0 |
Ejemplares similares
-
Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator
por: Althaus, Alison L., et al.
Publicado: (2020) -
A phase 1 double‐blind, placebo‐controlled study of zuranolone (SAGE‐217) in a phase advance model of insomnia in healthy adults
por: Bullock, Amy, et al.
Publicado: (2021) -
Open‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression
por: Kanes, Stephen J., et al.
Publicado: (2017) -
Brexanolone as adjunctive therapy in super‐refractory status epilepticus
por: Rosenthal, Eric S., et al.
Publicado: (2017) -
Foreword: INDEPTH WHO-SAGE study
por: Sankoh, Osman
Publicado: (2010)